Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.
Description for laymen
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.
JSON Data
{
"short_title": "IOV-LUN-202: Therapeutisch",
"data_mode": "900",
"data_mode_number": "000002203",
"official_title": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "second",
"ctgov_number": "NCT04614103",
"eudract_number": "2020-003629-45",
"general_contact_email": "ectu@ukdd.de",
"general_contact_phone": "+49 351-4587566",
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Dies ist eine prospektive, offene, multizentrische, nicht-randomisierte Phase-2-Studie zur Bewertung von LN-145 bei Patienten mit metastasiertem NSCLC.",
"description_laie_en": "This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.",
"description_expert_de": "Dies ist eine prospektive, offene, multizentrische, nicht-randomisierte Phase-2-Studie zur Bewertung von LN-145 bei Patienten mit metastasiertem NSCLC.",
"description_expert_en": "This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "II",
"main_cat_id": 10,
"sub_cat_id": 50
}
